Centanafadine, a promising medication for the treatment of ADHD, has recently been approved in the United States. This treatment is distinguished by its innovative mode of action, offering new perspectives for affected patients.
However, French specialists emphasize that this medication is not among the available options in France. They highlight the scarcity of molecules available in the country for treating this disorder, pointing out a gap in the therapeutic offerings.
Reach readers across the German-speaking world — get in touch
Your privacy
We would like to count which pages are read — with our own statistics on our own server in Frankfurt am Main. No cookies are set for that and nothing is stored on your device. We ask nevertheless before we count. Without your consent the site remains fully usable — nothing is missing.
